SCHEDULE: Vanguard Group Adjusts Vistagen Therapeutics Stake Below 5%

The Vanguard Group has filed an amended Schedule 13G, reporting a 4.62% beneficial ownership in Vistagen Therapeutics Inc. following an internal realignment.

Summary

• The Vanguard Group reported beneficial ownership of 1,824,738 shares of Vistagen Therapeutics Inc. common stock as of December 31, 2025.
• This ownership represents 4.62% of the class, placing The Vanguard Group below the 5% threshold for a Schedule 13D filing.
• The Vanguard Group holds shared voting power over 228,509 shares and shared dispositive power over 1,824,738 shares.
• An internal realignment at The Vanguard Group on January 12, 2026, means it no longer performs portfolio management or proxy voting services, and its subsidiaries will report beneficial ownership separately on a disaggregated basis.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Vistagen Therapeutics Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While Vanguard maintains a significant stake, the reduction below 5% by the parent entity due to internal realignment is a procedural change rather than a strong positive or negative signal for Vistagen Therapeutics Inc.

Positives

• The Vanguard Group, a major institutional investor, continues to hold a substantial stake of 4.62% in Vistagen Therapeutics Inc.
• The filing certifies that the investment is for ordinary course of business and not for the purpose of influencing control, indicating a stable, passive institutional presence.

Negatives

• The Vanguard Group's reported beneficial ownership has fallen below the 5% threshold, which, while explained by an internal realignment and disaggregated reporting, means the parent entity no longer reports a significant aggregated stake.

Risks

• No specific risks related to Vistagen Therapeutics Inc. are mentioned in this beneficial ownership filing.

Future Outlook

NA

Management Comments

• Ashley Grim, Head of Global Fund Administration for The Vanguard Group, certified that, to the best of their knowledge and belief, the information set forth in the statement is true, complete, and correct.
• The certification also states that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional filings like Schedule 13G provide transparency into major investors' positions. A large passive investor like Vanguard holding a stake, even if below 5% and disaggregated, signals continued market presence for Vistagen Therapeutics Inc. The internal realignment at Vanguard is a procedural change for the asset manager, impacting how its various entities report holdings, rather than a direct statement on Vistagen's prospects.

Management Changes

Stakeholder Impact

• Shareholders: Provides transparency on a major institutional investor's stake. The disaggregation of Vanguard's reporting might lead to a perception of reduced aggregate institutional ownership from Vanguard as a single entity, though the underlying holdings remain within the Vanguard ecosystem.

Next Steps

• Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc. anticipate reporting beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on SEC Release No. 34-39538.

Key Dates

Recommendation

The filing indicates a passive investment by a major institutional investor, The Vanguard Group, which has adjusted its reporting structure. The stake is below 5% and is not intended to influence control. This is a routine disclosure and does not provide new fundamental information about Vistagen Therapeutics Inc. that would warrant a change in investment strategy.

Keywords

Vistagen Therapeutics, Vanguard Group, Schedule 13G, beneficial ownership, common stock, institutional investment, SEC filing, 92840H400, passive investment